VivoSim Labs presents NAMkind toxicity data at EUROTOX 2026
VivoSim Labs has presented new benchmark data at EUROTOX 2026 in Vienna, showing that its NAMkind™ platform can predict drug-induced liver injury (DILI) and gastrointestinal toxicity across both traditional small molecules and complex biologics such as antibody-drug conjugates (ADCs). The NASDAQ-listed San Diego company says the results strengthen the commercial case for its 3D human tissue models as an alternative to animal testing ahead of clinical development.
The release does not report formal validation statistics, market revenue, or the number of pharmaceutical partners currently using the platform, which limits independent assessment of the claims. What the data do include are concrete head-to-head comparisons: the NAMkind™ Liver platform ranked trastuzumab deruxtecan as significantly more hepatotoxic than trastuzumab emtansine, a finding with direct relevance to ADC developers navigating payload selection. In the intestinal model, transepithelial electrical resistance measurements detected mucosal barrier deterioration before cytotoxicity became overt, and human ileum tissue showed greater sensitivity to ADC-induced toxicity than colon tissue.
Extended culture duration as a differentiator
VivoSim points to the longevity of its culture systems as a key technical advantage. The NAMkind™ Liver platform supports spheroid viability for up to 28 days; the intestinal models maintain barrier integrity for up to three weeks. That duration matters because repeat-dose toxicity, the kind that often surfaces only after weeks of patient exposure, is poorly captured by conventional short-term assays. The company says this allowed it to rank clinical DILI risk across thiazolidinediones and NSAIDs, two reference compound classes with well-characterised clinical safety profiles, providing an implicit validation benchmark.
Chief scientific officer Amar Sethi said the extended-culture approach lets the company observe "micro-architectural and functional degradation that traditional short-term assays may miss," adding that multi-endpoint profiling produces "human-relevant translational signatures to optimise compound selection and de-risk pipelines."
Regulatory tailwind and competitive context
VivoSim is positioning itself to benefit from a regulatory shift that is reshaping preclinical safety science. The FDA's ongoing efforts to accelerate the adoption of New Approach Methodologies (NAMs) and reduce reliance on traditional animal models create a structural opportunity for companies offering validated human-tissue alternatives. The press release is careful to note that the regulatory momentum does not constitute an endorsement of VivoSim's platform specifically, which is an important caveat for investors.
The NAM preclinical services market is attracting a number of players, ranging from organ-on-a-chip companies such as Emulate and CN Bio to larger contract research organisations building in-house three-dimensional tissue capabilities. VivoSim's differentiation rests on the duration and complexity of its culture systems and, increasingly, on its demonstrated applicability to ADCs, a modality that has seen significant clinical and commercial momentum across oncology in recent years. The ability to deconvolute payload versus linker toxicity is a commercially relevant capability, given that ADC clinical attrition has historically been driven by off-target tissue damage.
The EUROTOX presentation adds a scientific disclosure milestone to the VivoSim story, but broader commercial validation will depend on whether pharmaceutical partners publicly disclose their adoption of the platform and whether regulatory agencies begin citing NAM data packages in approval decisions. Both are longer-dated catalysts than a conference poster, and investors should weigh the EUROTOX data accordingly.